Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
about
NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivoKinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanomaMiR-21: an environmental driver of malignant melanoma?Positional plasticity in regenerating Amybstoma mexicanum limbs is associated with cell proliferation and pathways of cellular differentiation.Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.Systematic morphological profiling of human gene and allele function via Cell Painting.Cyclin-dependent kinases as therapeutic targets in melanoma.Repression of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.Signal Sequence Receptor 2 is required for survival of human melanoma cells as part of an unfolded protein response to endoplasmic reticulum stress.Dual c-Jun N-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma.Exploring inhibitory potential of Curcumin against various cancer targets by in silico virtual screening.Analysis of microRNA-203 function in CREB/MITF/RAB27a pathway: comparison between canine and human melanoma cells.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinoma.CDK4 inhibitors an emerging strategy for the treatment of melanoma
P2860
Q21132689-09671E64-0FA2-4D9A-9D8D-858E3E840806Q35706499-DCE101D0-7396-4EFC-92FD-F9393D453448Q35786021-2158AE85-37F3-4BE9-9FE0-5EBD6A765BD4Q35849238-9F6F92EE-FA6B-4185-94B8-8F4A1D434A0BQ36774894-52865480-5C0E-4B58-BAF7-09385B7547ECQ37745645-80A45BA1-B612-4050-B580-9EDF6A6BB835Q38177036-7DA141CB-E411-4806-9EC5-ECD31C5A7F7FQ38728895-9C85A83F-CE70-43CF-AFAB-C325045F340EQ38770829-6B5B948B-0BFA-45A2-A2E4-7EC20B928349Q40687706-80F5915F-F488-445B-896A-D475578D98F6Q45253639-72E5F819-B073-40C7-BA5F-98911ACF99F3Q46830544-F7E87E2B-7881-4B14-A71F-66EDE3E145C6Q47227422-5F4E4183-9C82-41E6-B077-CA93DB57DCC0Q55425656-005A84FF-521D-4406-B7D9-ECF45094DB16Q57571832-78DCEFAC-CDF4-4FDF-9037-4E10ACC91803
P2860
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Dual suppression of the cyclin ...... and CDKN1A in human melanoma.
@ast
Dual suppression of the cyclin ...... and CDKN1A in human melanoma.
@en
type
label
Dual suppression of the cyclin ...... and CDKN1A in human melanoma.
@ast
Dual suppression of the cyclin ...... and CDKN1A in human melanoma.
@en
prefLabel
Dual suppression of the cyclin ...... and CDKN1A in human melanoma.
@ast
Dual suppression of the cyclin ...... and CDKN1A in human melanoma.
@en
P2093
P2860
P356
P1476
Dual suppression of the cyclin ...... C and CDKN1A in human melanoma
@en
P2093
Ahmad Jalili
Christine Wagner
David E Fisher
Gaurav Pathria
Georg Stingl
Jean-Philippe Brunet
Kirsten D Mertz
Mikhail Pashenkov
Sridhar Ramaswamy
Stephan N Wagner
P2860
P304
P356
10.1093/JNCI/DJS373
P407
P577
2012-09-20T00:00:00Z